In short:
Victoria has opened a new cell-based vaccine manufacturing plant in Sunbury, boosting Australia’s supply of critical vaccines and antivenoms while reducing reliance on overseas imports. The development comes as communities across Melbourne’s west continue to grapple with differing views on vaccination following the Covid pandemic, mandates and lockdowns.
Vaccine Production Closer to Home
Australia’s vaccine manufacturing capability is set for a significant lift with the opening of the Southern Hemisphere’s first cell-based vaccine plant in Victoria.
The new CSL Seqirus facility in Sunbury, officially launched on 2 December, is designed to produce pandemic and seasonal influenza vaccines, antivenoms and Q-Fever vaccines, strengthening local access to critical medical supplies.
The plant is the result of a long-term agreement between the Australian Government, CSL Seqirus and the Victorian Government.
Under a $1 billion, 10-year arrangement, Seqirus will manufacture and supply these products nationally through to 2036.
The facility is expected to begin producing influenza vaccines early next year, followed by antivenoms and Q-Fever vaccines by mid-year.
Government ministers highlighted national self-sufficiency in future health emergencies, noting the challenges Australia faced during global supply shortages.
The project is also part of an effort to reduce reliance on international manufacturers by ensuring critical vaccines can be produced domestically.
Officials say the plant will create more than 350 high-skilled jobs, though it remains unclear how widely those opportunities will extend across Victoria’s workforce.
Advanced manufacturing roles often require specialist qualifications, meaning many positions may go to workers with existing experience in biomedicine, engineering or pharmaceutical production rather than to residents currently unemployed or seeking entry-level work.
For growing areas like Wyndham, which has a large pool of young jobseekers and workers transitioning from retail, logistics or trades, the direct employment impact may be limited unless targeted training pathways are developed.
Even so, local production can help reduce medical overheads by shortening supply chains, improving response times in emergencies and allowing national stockpiles to be replenished without depending on overseas suppliers.
Melbourne now hosts two major vaccine manufacturing hubs, giving Australia long-term access to both cell-based and mRNA technologies.
Minister Mark Butler said, “This new world-class manufacturing plant in Melbourne means we won’t have to wait in a queue to receive critical vaccines from overseas suppliers in an emergency. It will help ensure we are better prepared for the next pandemic.”
Victorian Minister Danny Pearson said, “This major investment cements Victoria as a global leader in cell-based influenza vaccines and strengthens our state’s research, commercialisation and advanced manufacturing capabilities.”
CSL Seqirus Senior Vice President Dave Ross said the company’s partnership with governments has shaped its long-term work in vaccine innovation.
For Wyndham residents, the broader benefits are likely to be felt through more reliable access to vaccines and antivenoms during health emergencies. However, vaccines remain a contentious topic across many communities following the Covid pandemic, vaccine mandates and extended lockdowns.
While the facility increases Australia’s manufacturing capacity, public confidence and attitudes toward vaccination continue to differ widely, shaping how developments like this are received locally.
FOLLOW US
